178748-05-5Relevant articles and documents
Discovery of Orally Bioavailable Ligand Efficient Quinazolindiones as Potent and Selective Tankyrases Inhibitors
Qin, Donghui,Lin, Xiaojuan,Liu, Zhi,Chen, Yan,Zhang, Zhiliu,Wu, Chengde,Liu, Linlin,Pan, Yan,Laquerre, Sylvie,Emery, John,Fergusson, Jeff,Roland, Kimberly,Keenan, Rick,Oliff, Allen,Kumar, Sanjay,Cheung, Mui,Su, Dai-Shi
, p. 1005 - 1010 (2021/05/27)
We report herein the discovery of quinazolindiones as potent and selective tankyrase inhibitors. Elucidation of the structure-activity relationship of the lead compound 1g led to truncated analogues that have good potency in cells, pharmacokinetic (PK) properties, and excellent selectivity. Compound 21 exhibited excellent potencies in cells and proliferation studies, good selectivity, in vitro activities, and an excellent PK profile. Compound 21 also inhibited H292 xenograft tumor growth in nude mice. The synthesis, biological, pharmacokinetic, in vivo efficacy studies, and safety profiles of compounds are presented.
QUINAZOLINEDIONES AS TANKYRASE INHIBITORS
-
, (2014/01/07)
This invention relates to the use of quinazolinediones for the modulation, notably the inhibition of the activity of tankyrases (TNKS1 and TNKS2). Suitably, the present invention relates to the use of quinazolinediones in the treatment of cancer, fibrosis and other hyperproliferative diseases through this mechanism.